ArticleBMC gastroenterology2026
Creatinine-to-body weight ratio as an independent predictor of hepatic steatosis severity in metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is closely tied to systemic metabolic dysregulation, yet reliable biomarkers of steatosis severity remain limited. The creatinine-to-body weight (Cr/BW) ratio, a surrogate for muscle mass and renal function, has been proposed as a predictor of MASLD; however, its correlation with hepatic steatosis severity, quantified by the controlled attenuation parameter (CAP), remains poorly defined.
methodsIn this cross-sectional study of 1,492 participants (946 MASLD; 546 non-MASLD), we evaluated the association between the Cr/BW ratio and CAP-measured steatosis severity (mild, moderate, or severe) using ordinal logistic regression. Nonlinear relationships were explored using restricted cubic splines (RCS), and predictive performance was assessed using the area under the receiver operating characteristic curve (AUROC). To ensure robustness, subgroup analyses were conducted by age and sex.
resultsSevere MASLD (CAP ≥ 295 dB/m) was associated with a significantly lower Cr/BW ratio (median 0.89 vs. 1.03 in mild steatosis; P < 0.001). The Cr/BW ratio independently predicted steatosis severity (adjusted OR per 0.1-unit decrease: 0.03; 95% CI: 0.02–0.05; P < 0.001). RCS analysis revealed a threshold effect, and the risk of severe steatosis rose sharply below a Cr/BW ratio of 1.01 (OR = 0.02; 95% CI: 0.01–0.05). The AUROC for the Cr/BW ratio was 0.72, outperforming traditional metabolic markers. The findings were also consistent across age and sex subgroups.
conclusionThe Cr/BW ratio is inversely and independently associated with the severity of hepatic steatosis in MASLD. A threshold of 1.01 may serve as a marker to identify high-risk patients, supporting its integration into clinical screening and management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.